Newsfeeds - Spark Newswire

3 minute read

FDA
News

Jounce Therapeutics Says Progresses INNATE Study Of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy And Pimivalimab (PD-1 Inhibitor) Combination Therapy In Patients With Advanced Solid Tumors

Today, 3:55 AM

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the initiation of patient enrollment

JNCE

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 3:55 AM

AEMD

4 minute read

46 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:55 AM

Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.

ACH

3 minute read

36 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 3:55 AM

Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results.

ACH

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 14, 2021

By Benzinga Insights

Today, 3:55 AM

AADI

1 minute read

Raymond James Upgrades Jounce Therapeutics to Outperform, Announces $10 Price Target

By vishwanath@benzinga.com

Today, 3:55 AM

Raymond James analyst Steven Seedhouse upgrades Jounce Therapeutics (NASDAQ:JNCE) from Market Perform to Outperform and announces $10 price target.

JNCE

7 minute read

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO

By Shanthi Rexaline

Today, 3:55 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)

ABSI

1 minute read

Jounce Therapeutics Q2 EPS $(0.08) Beats $(0.36) Estimate

By Bill Haddad

Today, 3:55 AM

Jounce Therapeutics (NASDAQ:JNCE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.36) by 77.78 percent. This is a 90.24 percent increase over losses of $(0.82) per share

JNCE

34 minute read

Earnings Scheduled For August 5, 2021

By Benzinga Insights

Today, 3:55 AM

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.

AAOI

6 minute read

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

By Shanthi Rexaline

Today, 3:55 AM

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

ABUS